Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference
CCORF Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $26
CCORF analyst Sumant Kulkarni maintains $Annovis Bio(ANVS.US)$ with a buy rating, and maintains the target price at $26.According to TipRanks data, the analyst has a success rate of 42.0% and a
Buy Rating on Annovis Bio Amid Progress in PD and AD Drug Development
Annovis Bio, Inc. (NYSE:ANVS) Surges 24%; Retail Investors Who Own 56% Shares Profited Along With Insiders
Maxim Group Maintains Annovis Bio(ANVS.US) With Hold Rating
Maxim Group analyst Jason McCarthy maintains $Annovis Bio(ANVS.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 24.4% and a total average return of -22.1% over
Annovis Bio (ANVS) Receives a Hold From Maxim Group